Compared with other studies of CGM use among people with type 2 diabetes not on insulin therapy, the A1c change described in this study was lower (−0.45% crude or −0.28% after adjusting for covariates) compared to −3.0% in Grace [12] and –1.6% in Wright [11]. This evidence concerns the gene INS and type 2 diabetes mellitus.